Logo image
Evaluation of the anti-endotoxin effects of polymyxin B in a feline model of endotoxemia
Journal article   Peer reviewed

Evaluation of the anti-endotoxin effects of polymyxin B in a feline model of endotoxemia

C.R. Sharp, A.E. DeClue, C.E. Haak, A.R. Honaker and C.R. Reinero
Journal of Feline Medicine and Surgery, Vol.12(4), pp.278-285
2010
url
Link to Published Version *Subscription may be requiredView

Abstract

Directed, effective therapies for feline sepsis are needed to reduce the high morbidity and mortality associated with this disease. We investigated the anti-endotoxin effects of polymyxin B (PMB) in a blinded, placebo controlled fashion, both ex vivo in a feline whole blood culture system and in vivo, using a low-dose endotoxin infusion in cats. Serial measures of systemic inflammation, and hemodynamic stability, were compared between groups. Ex vivo, PMB significantly decreased lipopolysaccharide-induced tumor necrosis factor (TNF) production from whole blood. PMB (1 mg/kg over 30 min) demonstrated anti-endotoxin effects in vivo, including decreased peak plasma TNF activity (P<0.001) and increased white blood cell count (P=0.019), with no adverse effects. Given the apparent safety and anti-endotoxin effects of PMB in this endotoxemia model, a carefully designed, randomized, blinded, placebo controlled clinical trial evaluating the use of PMB in naturally occurring Gram-negative feline sepsis should be considered.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.6 Immunology
1.6.351 Sepsis Immunology
Web Of Science research areas
Veterinary Sciences
ESI research areas
Plant & Animal Science
Logo image